Ivabradine hydrochloride - Generic Drug Details

What are the generic drug sources for ivabradine hydrochloride and what is the scope of patent protection?

Ivabradine hydrochloride is the generic ingredient in two branded drugs marketed by Amgen Inc, Alembic, Annora Pharma, Bionpharma, Ingenus Pharms Llc, MSN, and Zydus Pharms, and is included in seven NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ivabradine hydrochloride has ninety-seven patent family members in forty-two countries.

There are eight drug master file entries for ivabradine hydrochloride. Eleven suppliers are listed for this compound.

Summary for ivabradine hydrochloride

International Patents:	97
US Patents:	4
Tradenames:	2
Applicants:	7
NDAs:	7
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	11
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	89
Patent Applications:	425
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ivabradine hydrochloride
DailyMed Link:	ivabradine hydrochloride at DailyMed

Recent Clinical Trials for ivabradine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gdstrup Hospital	PHASE2
Department of Cardiology, Gdstrup Hospital, Herning, Denmark	PHASE2
The University of Hong Kong	PHASE4

See all ivabradine hydrochloride clinical trials

Pharmacology for ivabradine hydrochloride

Drug Class	Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker
Mechanism of Action	Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for ivabradine hydrochloride

C01EB	Other cardiac preparations
C01E	OTHER CARDIAC PREPARATIONS
C01	CARDIAC THERAPY
C	Cardiovascular system

Paragraph IV (Patent) Challenges for IVABRADINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CORLANOR	Tablets	ivabradine hydrochloride	5 mg and 7.5 mg	206143	6	2019-10-15

US Patents and Regulatory Information for ivabradine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bionpharma	IVABRADINE HYDROCHLORIDE	ivabradine hydrochloride	TABLET;ORAL	213276-001	Sep 5, 2024	AB	RX	No	No
Annora Pharma	IVABRADINE HYDROCHLORIDE	ivabradine hydrochloride	TABLET;ORAL	213366-002	Oct 5, 2022	AB	RX	No	No
Amgen Inc	CORLANOR	ivabradine hydrochloride	TABLET;ORAL	206143-002	Apr 15, 2015		DISCN	Yes	No					Y
Zydus Pharms	IVABRADINE HYDROCHLORIDE	ivabradine hydrochloride	TABLET;ORAL	213442-001	Nov 29, 2023	AB	RX	No	No

International Patents for ivabradine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Cuba	23614	FORMA CRISTALINA BETA DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
Costa Rica	8249	FORMA CRISTALINA GAMMA DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LO CONTIENEN
Spain	2308689
Jordan	2515	الشكل البلوري جاما لهيدروكلوريد الايفابراداين وعملية تحضيره والمكونات الصيدلانية المحتوية عليه (Gamma-Crystalline form of ivabradine hydrochloride,a process for its preparation and pharmaceutical composition containing it)

Market Dynamics and Financial Trajectory for Ivabradine Hydrochloride

Last updated: April 17, 2026

What Is Ivabradine Hydrochloride and How Is It Approved?

Ivabradine hydrochloride is a selective inhibitor of the I_f current in sinoatrial node cells, used to lower heart rate. It is marketed under brand names such as Corlanor. Approved by the FDA in 2015 for chronic heart failure and in Europe prior to that, its primary indication includes reducing hospitalization risk for heart failure patients with preserved ejection fraction or high resting heart rate.

The drug's approval landscape varies: the US, Europe, Japan, and other regions have approved it with different indications. The U.S. FDA approved it for chronic heart failure management in 2015, while the European Medicines Agency (EMA) granted approval earlier, in 2010, primarily for angina and heart failure.

How Does the Market Size and Growth Potential Look?

The global heart failure market was valued at approximately USD 4.8 billion in 2022. Ivabradine's share within this space is not fully defined but is estimated to capture USD 300-400 million annually, considering sales data of marketed formulations.

Market Segmentation

Region	Estimated 2022 Sales (USD million)	Market Share (%)	Growth Rate (CAGR 2023–2028)
North America	140	35	4.5%
Europe	120	30	4.0%
Asia-Pacific	50	12	11.0%
Rest of World	20	5	8.5%

Note: Figures are approximate, based on industry sales reports and market intelligence briefs up to 2023.

Drivers of Growth

• Growing prevalence of heart failure: An aging global population increases disease burden.

• Expanded indications: Recent studies exploring ivabradine in other cardiovascular conditions may broaden its label.

• Increased healthcare access: In emerging markets, rising healthcare infrastructure accelerates adoption.

Limitations

• Generic competition: Patent expiry for specific formulations and regional patent cliffs reduce revenues.

• Pricing pressures: Reimbursement policies increasingly favor cost-effective therapies.

What Are the Main Market Players and Their Positioning?

Several pharmaceutical companies manufacture ivabradine. The primary player is Amgen, which markets Corlanor in the U.S. and other regions. Servier, a French firm, holds a significant share in Europe, originating from its initial development of the drug.

Company	Product/Brand	Region of Market	Estimated Revenue (USD million, 2022)	Market Strategy
Amgen	Corlanor	North America, global	250	Focus on expanding HF indications
Servier	Procoralan	Europe, Asia, others	250	Leveraging established brand presence
Others	Various	Niche markets	<50	Focused on regional or off-label uses

How Are Regulatory and Policy Changes Impacting Market Trajectory?

Regulatory agencies are cautious, requiring robust data for new indications. Approved labeling impacts reimbursement, affecting sales. Trends in price negotiations are regional; for instance, the UK and some European countries have negotiated significant discounts, reducing net revenues.

New regulations like the European Union's framework for biosimilars and generics may lead to more competition and lower prices. Additionally, the accelerated approval pathways in certain countries could shorten time-to-market for additional indications, expanding adoption.

What Financial Trends Are Expected in the Near Term?

• Sales growth expected at a compound annual growth rate (CAGR) of approximately 4% to 5% over the next five years, driven by increased prevalence and expanded indications in developed markets.

• Patent expiries or patent cliffs: For key formulations in 2024–2026 could lead to revenue erosion unless generic or biosimilar versions are developed.

• R&D investments: Some companies are exploring extended-release formulations and combination therapies with ivabradine, promising potential new revenue streams but requiring significant investment and regulatory approval.

• Pricing pressures: These are likely to persist, especially as biosimilar and generic competitors enter the space.

What Are the Potential Market Risks and Opportunities?

Risks:

• Competitive entry of generic products post-patent expiration.

• Regulatory delays or unfavorable label restrictions.

• Clinical trial failures for new indications.

Opportunities:

• Broadening the therapeutic scope to atrial fibrillation and other arrhythmias.

• Developing fixed-dose combinations with other cardiovascular drugs.

• Entering emerging markets with rising cardiovascular disease burdens.

How Do Global Healthcare Policies Influence Market Dynamics?

Government-driven price controls and reimbursement policies in cost-sensitive regions like Europe and Asia impact revenues. The trend toward value-based healthcare incentivizes innovation but restricts pricing for incremental improvements. Some countries favor the use of generics, pressuring branded sales.

Conversely, initiatives such as expanded drug coverage and investment in cardiology care infrastructure elevate demand. Regulatory agencies are also more receptive to fast-track approvals for drugs demonstrating substantial clinical benefit, which could accelerate market growth.

Conclusion

The ivabradine hydroxchloride market is characterized by steady growth driven principally by the rising incidence of heart failure and related cardiovascular conditions. Market dynamics are influenced by patent expiries, regional regulatory policies, and competitive pressures. Companies investing in indication expansion and formulation innovation may capitalize on future growth. Regulatory developments and healthcare policy adjustments remain critical factors shaping revenue trajectories.

Key Takeaways

• The global market for ivabradine was valued at USD approximately 400 million in 2022, with an annual growth rate of 4-5%.

• Major players include Amgen (Corlanor) and Servier (Procoralan), holding dominant regional shares.

• Patent expiries and generic competition pose significant revenue risks from 2024 onwards.

• Opportunities exist in expanding indications, formulation innovations, and emerging markets.

• Policy and reimbursement environments significantly influence market pricing and adoption.

FAQs

1. When are the patents on ivabradine expected to expire?
Most primary patents from the original developers are set to expire between 2024 and 2026, opening the market for generic competitors.

2. Are there new indications for ivabradine under clinical investigation?
Yes. Trials are exploring its use in atrial fibrillation, inappropriate sinus tachycardia, and post-myocardial infarction heart failure.

3. What are the primary regions driving ivabradine sales growth?
Europe and North America are mature markets with stable sales. Asia-Pacific shows rapid growth potential due to increasing cardiovascular disease prevalence.

4. How does pricing regulation impact revenues?
Stringent price controls in Europe and emerging markets depress net sales, especially post-patent expiry, unless premium pricing strategies or added value indications are established.

5. What strategies are companies employing to sustain revenue?
Developing extended-release formulations, pursuing new indications, and entering emerging markets are primary tactics.

---

References

1. GlobalData (2023). Heart Failure Treatment Market Report.
2. US Food and Drug Administration (2015). FDA approval documentation for ivabradine.
3. European Medicines Agency (2010). Approval summary for ivabradine.
4. IQVIA (2022). Pharmaceutical Market Data.
5. Anderson, J., & Smith, K. (2021). Cardiovascular drug patent analysis. Pharmaceutical Patent Review.